FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
Marc Wolman
Advertisement
Articles by Marc Wolman
Advertisement
Latest Updated Articles
Viral Vector API Characterization of Product-Related ImpuritiesPublished: October 16th 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
Regulatory Challenges for Global Manufacturing of Vaccines
4
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
5
